Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity
NCT01108601
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Hearing Loss
Interventions
DRUG:
Ringer's Lactate (0.03% Ciprofloxacin)
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre